Numerous Hints Suggest Final Death Of Oxford Cannabinoid Technologies Holdings – Shizzle My Fizzle | Cannabis Law Report | Where to buy Skittles Moonrock online
Learn where to buy CBD online. TOP QUALITY GRADE A++
Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.
👉 Click here to Visit our shop! 🛒
This story is almost an exact duplicate of the story i reported yesterday about Australian company Ecofibre.. lots of money, the business of science and cannabinoids and so on and so forth… all of which ends in ingnomy
Remember amongst the investors were Casa Verde Capital, the cannabis-focused venture capital firm in which Snoop Dogg is a partner
They invested in Oxford Cannabinoid Technologies (OCT) making a $10 million investment in OCT in 2018 and held around a 2% stake in the company post-IPO.
Other investors included (Source Perplexity)
, a subsidiary of Imperial Brands PLC, took an equity stake in OCT in 2018. Imperial Brands highlighted their interest in supporting OCT’s cannabinoid research and gaining insight into the medical cannabis market through this investment16.
was a significant shareholder in OCT. Kingsley held a substantial stake but reduced it over time; for example, their holding fell from 20.76% to 14.95% as they sold shares. Kingsley’s managing partner, Neil Mahapatra, also personally invested in OCT and was involved as a non-executive director. Kingsley has been described as the largest shareholder in OCT35.
Australian US Company Eco Fibre borrows $AUD4 million to try & save itself from freefall
Business of Cannabis reports
Oxford Cannabinoid Technologies Holdings, one of the UK’s few remaining pharmaceutical cannabis companies, appears to have entered administration.
Like many early-stage biotech companies, OCTH, the holding company of its trading entity Octavian Therapeutics, had always been reliant on investment to push forward its clinical trials.
While there has been no official statement from the company or its administrators, Rushtons Insolvency Limited, numerous public filings confirm they have been appointed.
As such, their promising drug development pipeline, alongside valuable intellectual property for any similar biotech operators, is now likely up for grabs.
Its collapse is reflective of a wider crisis in the global biotech sector, particularly in the US where OCT saw its future, seeing widespread job cuts, a significant slowdown of M&A activity, and public investment opportunities all but grind to a halt.
What happened?
On Friday, May 09, 2025, notice that OCTH had appointed administrators was published in The Gazette, the UK’s official public record of insolvency proceedings.
According to the filing, on May 02, Nicola Baker of Rushtons Insolvency Limited, was appointed as the company’s administrator.
Business of Cannabis has contacted OCT, its communications provider, and the administrators, but as of the date of publication has received no response to our enquiries.
However, a filing from AIM-listed Dillistone Group Plc (DSG), where OCT’s non-executive director and former Chair Julie Pomeroy is also a director, appeared to confirm the administration.
Under Rule 17 and Schedule 2, Paragraph (G) of the AIM Rules for Companies, listed companies must detail any directorships in any other companies held by their directors.
Read full report
Leave a Reply
Want to join the discussion?Feel free to contribute!